Two studies reported that the poor or intermediate metabolizer of CYP2D6 was not associated with the clinical outcome of postmenopausal Caucasian women patients with HR-positive operable invasive breast cancer receiving adjuvant tamoxifen [46, 47]. Here, CYP2D6 is linked to invasive breast carcinoma.